Innovent, AnHeart present interim data from Taletrectinib Phase 2 trial
Category: #health  By Mateen Dalal  Date: 2021-09-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Innovent, AnHeart present interim data from Taletrectinib Phase 2 trial

Innovent Biologics, Inc., a biopharmaceutical company, and AnHeart Therapeutics Co., Ltd. have jointly announced interim clinical data from a Phase 2 trial (TRUST) evaluating Taletrectinib (AB-106), an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive NSCLC (non-small cell lung cancer).

The results were presented as a keynote on September 25th-29th, 2021, at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting.

According to sources close to the trial, taletrectinib was well tolerated with treatment-related adverse events being gastrointestinal side effects, reversible aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels rising.

Dr. Caicun Zhou, Director of the Department of Oncology in Shanghai Pulmonary Hospital, stated that they are delighted by the interim Phase 2 results, which suggest that taletrectinib is a safe and acceptable new treatment for patients with ROS1 fusion-positive lung cancer.

Responses appear to be more spectacular in crizotinib treatment-naive patients. While the number of crizotinib pre-treated patients is small, most patients appear to be benefiting from the medication so far.

As per Dr. Hui Zhou, Senior VP, Innovent, said that their firm is pleased to see the interim Phase 2 data of taletrectinib to be presented at the CSCO event.

ROS1-positive patients currently have limited treatment options in China, claims Dr. Zhou. New therapies are needed urgently, and taletrectinib has good safety and efficacy results, which offers good treatment chances to patients with ROS1 fusion-positive NSCLC.

Bing Yan, MD, Chief Medical Officer and Co-founder of AnHeart Therapeutics, claims that their team is focused on finalizing patient enrollment for its Phase 2 TRUST trial.

The interim data builds a strong foundation for its ongoing taletrectinib clinical trial. AnHeart sincerely express gratitude towards the patients, families and investigators in the TRUST trial and are looking forward to advancing new development in taletrectinib.

Source Credit - https://www.prnewswire.com/news-releases/innovent-and-anheart-announce-interim-data-from-phase-2-trial-of-taletrectinib-in-ros1-positive-nsclc-at-the-csco-2021-annual-meeting-301385147.html

 

 

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Google’s business intelligence platform Looker collabs with Tableau
Google’s business intelligence platform Looker collabs with Tableau
By Mateen Dalal

Google Cloud Platform has recently revealed that its business intelligence platform, Looker has been integrated with Tableau, empowering users of both the platforms to benefit from the different features offered by each. For starters, Google Cloud a...

HR tech firm Personio ropes in $270 million in latest financing round
HR tech firm Personio ropes in $270 million in latest financing round
By Mateen Dalal

Personio, a HR software provider targeting small and medium sized businesses, has attained a $270 million investment in the wake of high demand for its services. With the latest Series E round of funding, Personio's valuation roses to $6.3 billi...

New Zealand prepares to deal with potential surge in COVID-19 cases
New Zealand prepares to deal with potential surge in COVID-19 cases
By Mateen Dalal

New Zealand is preparing for an increase in Covid-19 cases after registering 94 new infections over the weekend, with pandemic modelers predicting that if the government continues on its present path, new cases would rapidly exceed 100 per day. Epid...